Compare Cintas Corporation (CTAS) vs Novavax Inc (NVAX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Cintas Corporation vs Novavax Inc — how do they compare? Cintas Corporation trades at $202.41 (market cap $79.86B), while Novavax Inc trades at $12.75 (market cap $1.82B). The key difference: Cintas Corporation is far larger — about 43.9× Novavax Inc's market cap, and Cintas Corporation pays a 1.03% dividend while Novavax Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold Cintas Corporation for 125 Days and Novavax Inc for 59 Days on average.
| CTAS | NVAX | |
|---|---|---|
Market Cap | $79.86B | $1.82B |
Volume | 1,323,583 | 6,198,505 |
Sector | Industrials | Health |
52-Week High | $216.53 | $12.75 |
52-Week Low | $163.55 | $6.22 |
Typical Hold Time | 125 Days | 59 Days |
Enterprise Value | $82.33B | $1.39B |
Dividend Yield | 1.03% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Cintas (CTAS) trades at $201.12, up 1.99% with a bullish technical signal. The company reported strong Q1 2027 results with revenue reaching $3.01 billion (10.9% growth) and earnings of $1.39 per share beating estimates. Fundamentals show robust profitability with 17.82% net margin and 41.25% ROE, though valuation ratios remain elevated at P/E 39.67. Recent guidance increases and consistent dividend growth support positive momentum.
The outlook remains positive with analyst consensus target of $234.60 (16.6% upside) and 40% buy ratings. Key risks include premium valuation multiples and potential economic sensitivity. The stock offers quality fundamentals but requires monitoring of margin sustainability and competitive pressures in the uniform services sector.
Novavax (NVAX) trades at $11.01, down 1.87% on the day, with a bullish technical signal from moving averages and a strong buy consensus from analysts (73.9% buy ratings). The company reported a net income of $440.3M in 2025, a significant turnaround from prior losses, though 2026 projections show a return to negative margins. Recent news highlights regulatory approvals for its COVID-19 vaccine and strategic pivots toward its Matrix-M adjuvant platform through partnerships.
The outlook is mixed: near-term catalysts include partnership-driven growth and vaccine approvals, but persistent cash burn and projected 2026 losses pose risks. Investor sentiment is buoyed by recent earnings beats and strategic shifts, yet execution on profitability remains critical for sustained upside.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Cintas Corporation
In its core uniform and facility services unit (78% of sales), Cintas provides uniform rental programs to businesses across the size spectrum, mostly in North America. The firm is by far the largest provider in the industry. Facilities products generally include the rental and sale of entrance mat, mops, shop towels, hand sanitizers, and restroom supplies. Cintas also runs a first aid and safety services business (11% of sales), a fire protection services business (7% of sales), and a uniform direct sales business (4% of sales).
Read more on CTAS →About Novavax Inc
Novavax, Inc. is a clinical stage biotechnology company. The Company creates novel vaccines to address a broad range of infectious diseases worldwide using proprietary virus-like particle (VLP) technology.
Read more on NVAX →
